Besançon CHU is one of the ten French establishments that have been clinically testing a new type of treatment for HER2-type breast cancer for the past three years. This breast cancer affects 100 of the 800 patients with breast cancer each year in Franche-Comté, and for three years the results have been spectacular. Meeting with Chantal BLIND cured of HER2-type breast cancer; She was one of the first to benefit from this treatment called T-DM1.
Jt Franche County Evening - Producteur: France 3 Besançon
Licence:
Turnkey
×
Mediaclip turnkey licences
Accessible rights for all uses, in the whole world, in accordance with our T&Cs.
Digital Publication : use for editorial publications - to inform the general public or illustrate the news - for digital broadcast on services, valid for 5 years.
Corporate/Brand content : use for the presentation and promotion of an image, brand, history and values of the Contracting Partner company - or, where applicable, the Beneficiary - for digital broadcast on its services and/or for Events, valid for 1 year.
Cultural Licence : use for cultural purposes and restricted to members of the cultural network. Digital publication for a term of 5 (years) and Events for a term of 1 (one) year from the order payment date.
The INA Galaxy 
Back
